# A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection

> **NCT04569838** · PHASE2 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 91 (actual)

## Conditions studied

- Indolent B-Cell Non-Hodgkin's Lymphomas

## Interventions

- **DRUG:** Bendamustine hydrochloride injection

## Key facts

- **NCT ID:** NCT04569838
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04569838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04569838, "A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04569838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*